Investments, and big commercial and industrial partners in the food/agriculture/cosmetics/health fields

The MeNow AI platform is actively searching for additional investments and commercial/industrial partners in the food/agriculture/cosmetics/health industry

The service is highly scalable due to its AI-driven, cloud- and HPC-enabled architecture. Once the underlying models and workflows are established, additional molecules, datasets, and clients can be onboarded with limited marginal cost. The platform supports parallel simulations and analyses, allowing the evaluation capacity to scale efficiently from small, customised assessments to larger screening campaigns.

Scalability is further enabled by the modular design of the service, which allows the number of molecules analysed, biological endpoints assessed, and depth of simulation to be adjusted according to client needs. As demand grows, computational resources can be expanded through cloud and HPC infrastructure without fundamental changes to the platform, supporting growth across multiple clients and markets simultaneously.

The service is highly replicable, as it is based on a standardised, AI-driven platform and well-defined computational workflows. The evaluation process follows repeatable protocols for data input, model execution, and results generation, ensuring consistent outputs across different molecules, clients, and use cases.

Replicability is further supported by the modular architecture of the platform, which allows the service to be deployed across different therapeutic or application domains by adapting input parameters, biological endpoints, and simulation settings without redesigning the core system. Standard onboarding, reporting templates, and presentation formats enable the service to be reproduced efficiently for multiple clients and markets while maintaining quality and comparability of results.

MeNow’s AI-driven platform enhances sustainability by enabling digital evaluation of natural compounds, reducing the need for resource-intensive lab experiments. Its predictive modeling identifies anti-inflammatory and anti-photoaging activity, optimizes synergistic combinations, and supports safer, more targeted formulations, minimizing raw material use and waste. By leveraging AI to upcycle botanical by-products and optimize extraction, MeNow contributes to a circular economy and lowers environmental impact. Faster, in-silico R&D shortens innovation cycles, reducing emissions and energy use, while its scalable, digital approach ensures that sustainability benefits grow with adoption, promoting efficient, responsible product development across personal care, functional food, and wellness sectors.